ELISA News and Research

RSS

Why did influenza fail to spread in a crowded indoor setting?

The EMIT-2 trial shows zero influenza transmission despite ideal conditions, suggesting a perfect storm is needed for the virus to spread effectively.

4 Feb 2026

Immune system dysfunction may fuel progressive heart failure after heart attacks

When the heart's muscle is weakened or injured due to a heart attack, it can make it hard for the heart to pump enough blood to meet the body's needs.

27 Jan 2026

Brain organoids reveal glioblastoma's secrets and therapy resistance

UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how the aggressive cancer interacts with surrounding brain cells and the immune system to become more invasive and resistant to therapy.

27 Jan 2026

Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with high hepatitis B virus prevalence.

24 Jan 2026

Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening

Sino Biological, Inc. is proud to announce the launch of its innovative SwiftFluo TR-FRET Kinase Assay Kits, a ready-to-use, high-performance solution designed to accelerate kinase activity detection and high-throughput kinase inhibitor screening.

From Sino Biological Inc. 21 Jan 2026

COVID-19 severity is linked to changes in mitochondrial DNA methylation

This study examined mitochondrial and nuclear-encoded mitochondrial DNA methylation in Indian patients with severe COVID-19 and found region-specific differential methylation linked to disease severity. Pathway analyses and protein assays implicated disrupted mitochondrial metabolism and dynamics, suggesting a role for mitochondrial epigenetic regulation in COVID-19 pathophysiology.

20 Jan 2026

Medicaid health plans step up outreach efforts ahead of GOP changes

Carmen Basu, bundled in a red jacket and woolly scarf, stood outside the headquarters of her local health plan one morning after picking up free groceries. She had brought her husband, teenage son, and 79-year-old mother-in-law to help.

22 Dec 2025

Ultra-processed foods linked to higher mortality in Black women with breast cancer

A study from Rutgers Cancer Institute researchers in eClinicalMedicine is the first to link ultra-processed foods to reduced survival in Black women with breast cancer.

18 Dec 2025

Supportive marriages may shape appetite control through oxytocin and the brain–gut axis

Supportive marital relationships are associated with lower BMI, fewer food addiction symptoms, higher oxytocin, stronger frontal brain responses to food cues, and favorable gut tryptophan metabolites. These coordinated social, neural, hormonal, and gut pathways suggest a plausible biological link between emotional support and healthier eating regulation.

8 Dec 2025

Extending the reach of Amperia™: Simplifying his-tagged protein quantification across expression and development workflows

Discover how Abselion’s Amperia™ platform delivers fast, reproducible His-tagged protein quantification with minimal prep, even from crude lysates.

From Abselion 27 Nov 2025

Focused ultrasound can be safely used in children being treated for brain cancer

Columbia University researchers are the first to show that focused ultrasound - a non-invasive technique that uses sound waves to enhance the delivery of drugs into the brain - can be safely used in children being treated for brain cancer.

19 Nov 2025

Switching APOE4 to APOE2 in adult mice reduces Alzheimer’s pathology and improves memory

Replacing APOE4 with APOE2 in adult mice rapidly reshapes brain lipids and gene expression, even after development is complete. This switch, especially when targeted to astrocytes, reduces amyloid burden, dampens gliosis, and improves associative memory despite E2-like peripheral lipid risks.

12 Nov 2025

Abselion launches His-Tagged Protein Quantification Kit and Sensors for Amperia at PEGS Europe 2025

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its Amperia™ assay portfolio with the launch of its Tagged Protein Quantification Kit | His-tag and Tagged Protein Sensor | His-tag Quantification.

10 Nov 2025

New radioimmunotherapy approach shows potential to cure HER2-positive breast cancer

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine.

7 Nov 2025

Top-five pharmaceutical company expands partnership with Aptamer for multi-target Optimer® development program

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.

4 Nov 2025

Low-cost biosensor identifies altered protein levels associated with psychiatric disorders

Brazilian researchers have developed a low-cost, portable biosensor that can quickly identify a protein whose altered levels are associated with psychiatric disorders, such as depression, schizophrenia, and bipolar disorder.

30 Oct 2025

Study reveals how a microglial mutation increases risk for Alzheimer's disease

Dominika Pilat, PhD, and Ana Griciuc, PhD, of the Department of Neurology at Massachusetts General Hospital are the lead and senior authors of a paper published in Neuron, "The Gain-of-Function TREM2-T96K Mutation Increases Risk for Alzheimer's Disease by Impairing Microglial Function."

17 Oct 2025

Engineered CAR-NK cells show enhanced cancer killing and immune evasion

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be programmed to attack cancer cells.

8 Oct 2025

Aptamer expands into targeted radiopharmaceuticals with major top 3 pharma contract

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, has announced a significant development contract with a top 3 global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals for potential therapeutic applications.